香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容 而引致之任何損失承擔任何責任。 山東新華製藥股份有限公司 Shandong Xinhua Pharmaceutical Company Limited （於中華人民共和國註冊成立之股份有限公司） （股份代碼：00719） 截至2023年9月30日止九個月之 未經審核季度業績公告 本公告乃根據《香港聯合交易所有限公司證券上市規則》（「上市規則」）第13.09條及第13.10B條 以及《證券及期貨條例》（香港法例第571章）第XIVA部項下的內幕消息條文（定義見上市規則） 而作出。 山東新華製藥股份有限公司（「本公司」）董事會（「董事會」）謹此宣佈本公司及其附屬公司（「本 集團」）截至2023年9月30日止九個月未經審核的綜合業績。本公告所載之財務資料均按照《中國企 業會計準則》（定義見上市規則）編製並經董事會及董事會審核委員會審視並核准。 本公司董事會、監事會及董事、監事、高級管理人員及主管會計工作負責人保證本公告內容的真實、 準確、完整 ...

山 東 新 華 製 藥 股 份 有 限 公 司 Shandong Xinhua Pharmaceutical Company Limited ( H 股股份代號：00719 ) (Ａ股股份代號：000756 ) 2023 中 期 報 告 目 錄 | --- | --- | |----------------------------------------------------|-------| | | | | 公司基本情況 | 2 | | 按《中國企業會計準則》編製的主要財務數據和財務指標 | 3 | | 股本變動及股東情況 | 6 | | 董事、監事、高級管理人員及員工情況 | 10 | | 董事長報告 | 22 | | 經營管理研討與分析 | 26 | | 重要事項 | 36 | | 公司管治 | 50 | | 財務報告 | 51 | | 備查文件 | 218 | 重要提示 本公司董事會、監事會及董事、監事、高級管理人員保證半年度報告內容的真實、準確、完整，不 存在虛假記載、誤導性陳述或重大遺漏，並承擔個別和連帶的法律責任。 本公司及其附屬公司（「本集團」）截至2023年6月30日止半年度財務報告未經審 ...

Financial Performance - Revenue for the six months ended June 30, 2023, was RMB 4,672,269,049.13, representing a 27.51% increase compared to RMB 3,664,294,993.33 for the same period in 2022[5] - Total profit for the same period was RMB 331,945,812.26, up 41.06% from RMB 235,316,728.47 in the previous year[5] - Net profit attributable to shareholders was RMB 269,807,157.85, reflecting a 38.80% increase from RMB 194,389,556.12 in the prior year[5] - Basic earnings per share increased to RMB 0.40, a rise of 33.33% compared to RMB 0.30 in the same period last year[5] - Operating revenue for the six months ended June 30, 2023, reached RMB 4,672,269,049.13, an increase of 27.51% compared to the same period in 2022[24] - The company's net profit for the six months ended June 30, 2023, was RMB 275,680,432.27, representing a 38.88% increase compared to the same period in 2022[24] - The total profit for the six months ended June 30, 2023, was RMB 331,945,812.26, a 41.06% increase year-on-year, driven by expanded sales scale and improved management efficiency[24] - The company reported a net profit margin for the reporting period of approximately 5.89%, compared to 5.42% in the previous year[5] Assets and Liabilities - The company's total assets as of June 30, 2023, were RMB 8,075,584,581.73, a decrease of 2.29% from RMB 8,265,131,332.13 at the end of 2022[5] - Total liabilities decreased by 9.96% to RMB 3,525,405,717.37 from RMB 3,915,226,169.32 at the end of 2022[5] - The company's total debt amounted to RMB 1,329,244,000, with cash and cash equivalents of RMB 979,173,000[30] - The asset-liability ratio stood at 43.66%, reflecting the company's financial stability[30] - Current assets totaled RMB 3,235,189,305.38, down from RMB 3,456,959,427.88, indicating a decrease of about 6.41%[46] - The company's cash and cash equivalents decreased to RMB 979,173,294.29 from RMB 1,158,741,565.90, a reduction of approximately 15.5%[46] - Total liabilities as of June 30, 2023, were RMB 3,525,405,717.37, down from RMB 3,915,226,169.32 at the end of 2022, indicating a reduction of approximately 9.9%[53][54] Operational Highlights - Domestic sales of active pharmaceutical ingredients (APIs) grew by 78.49% year-on-year, reflecting the company's strong market position[15] - Sales of industrial formulations increased by 48.66% year-on-year, while formulation processing and export business saw a remarkable growth of 93.97%[15] - The company launched 7 new products in the first half of 2023, including 5 formulation products and 1 active pharmaceutical ingredient[15] - A total of 10 drug production approvals and 6 veterinary drug approvals were obtained, marking a historical high for the company[16] - The company is advancing key projects, with construction completed for 4 projects, including DCB and methyldopa, now moving into equipment installation[15] - The company’s commercial segment achieved rapid growth, focusing on both pharmaceutical and non-pharmaceutical sectors[15] Research and Development - Research and development expenses increased by 39.72% year-on-year, totaling RMB 235,529,909.24, reflecting the company's commitment to technological innovation[24] - The company was granted 22 patents, including 8 invention patents, demonstrating its commitment to innovation[16] Cash Flow and Financial Management - The company reported a significant decrease in net cash flow from operating activities, which was RMB 20,131,070.66, down 89.67% from RMB 194,801,492.76 in the previous year[5] - Financial expenses decreased by 90.75% to RMB 1,341,987.35, attributed to optimized financing structure and increased foreign exchange gains[24] - Short-term borrowings rose by 106.31% to RMB 243,494,933.55, indicating a strategy to optimize the debt structure and reduce financing costs[23] Shareholder Information - As of June 30, 2023, the top shareholder, China Hualu Holdings Group Co., Ltd., held 30.36% of the shares, totaling 204,864,092 shares[8] - Hualu Holdings committed not to reduce its shareholding in the company within six months prior to the pricing benchmark date of the non-public A-share issuance[33] - Hualu Holdings promised to avoid any business or activities that may cause competition or conflict of interest with the company's main business during its control period[33] Compliance and Governance - The company has adhered to corporate governance codes during the reporting period without deviation[42] - The audit committee has reviewed the unaudited interim accounts for the six months ending June 30, 2023, and agreed with the financial accounting principles adopted[43] - The company has maintained compliance with the standards set forth in the "Standard Code" regarding securities trading, confirming no violations during the reporting period[45] Future Outlook - The company aims to obtain 6 new product production approvals, 1 raw material production approval, 2 clinical approvals, and 2 consistency evaluation approvals in the second half of the year[20] - The company plans to enhance market driving force by leveraging the diverse specifications of raw materials and expanding both export and domestic sales[19] - The company is actively expanding its pharmaceutical logistics and brand operations to improve profitability and accelerate growth[19] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[70]

Stock Options Incentive Plans - The company reported a total of 10,692,000 stock options granted under the 2018 A-share stock option incentive plan, with 5,167,800 options vested by the end of the reporting period[4]. - No stock options under the 2018 A-share stock option incentive plan have expired during the reporting period[5]. - The company has not granted stock options exceeding 1% of its total issued share capital to any participant, nor more than 0.1% in any 12-month period[5]. - As of December 31, 2022, there were no unvested stock options remaining for the participants under the 2018 plan[5]. - The company granted 9,035,400 stock options to other employee participants, with 4,339,500 options vested by the end of the reporting period[4]. - The company’s stock options have a waiting period of 24, 36, and 48 months, with specific exercise periods defined[5]. - The company’s stock options are structured to allow 34% to be exercised after 24 months, 33% after 36 months, and the remaining 33% after 48 months[5]. - The stock options under the 2021 A-share stock option incentive plan have a waiting period of 24, 36, and 48 months from the grant date, with 34% exercisable after 24 months[10]. - No stock options under the 2021 A-share stock option incentive plan have expired during the reporting period[10]. - The company has not granted or will grant options exceeding 1% of its total issued share capital to any participant, and no more than 0.1% in any 12-month period[10]. Compensation for Executives - The total compensation for key executives amounts to 3,870,000 RMB, with additional employee participants totaling 19,280,000 RMB, leading to a combined total of 23,150,000 RMB for the reporting period[8]. Company Governance - The company aims to further elaborate on its stock option incentive plan following the disclosure of its 2022 annual report[2]. - The company’s board of directors remains unchanged as of the announcement date, with key executives including the chairman and independent directors listed[11]. Stock Option Grants - The company granted 1,750,000 stock options to certain employee participants on December 26, 2022, with an exercise price of 37.53 RMB per share, and a fair value of 14.67 RMB per share at the grant date[9]. - The company has provided a summary of the stock option changes for the 2021 A-share stock option incentive plan, indicating ongoing management of employee incentives[5].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何 責任。 山東新華製藥股份有限公司 Shandong Xinhua Pharmaceutical Company Limited （於中華人民共和國註冊成立之股份有限公司） （股份編號：00719） 2023 年第一季度未經審核的業績 （本報告期由 2023 年 1 月 1 日至 2023 年 3 月 31 日止） 本公告乃根據香港聯合交易所有限公司證券上市規則（「上市規則」）第 13.09 條及第 13.10B 條及證券及 期貨條例（香港法例第 571 章）第 XIVA 部項下的內幕消息條文（定義見上市規則）而作出。 山東新華製藥股份有限公司（「本公司」）董事會（「董事會」）謹此宣佈本公司及其附屬公司（「本集 團」）截至 2023 年 3 月 31 日止三個月未經審核的綜合業績。本公告所載之財務資料均按照《中國企業會 計準則》（定義見上市規則）編製而且已經董事會審核委員會審視並核准。 本公司董事會、監事會及董事、 ...

山 東 新 華 製 藥 股 份 有 限 公 司 Shandong Xinhua Pharmaceutical Company Limited ( H股股份代號：0719 ) ( A股股份代號 : 000756 ) ( H Share Stock Code : 0719 ) ( A Share Stock Code : 000756 ) 2022 Annual Report 年 報 | --- | --- | --- | |----------------------------------------------------------------------------------------------------------------------|-------|--------------------------------------------------------------------------| | | | 目錄 CONTENTS | | 重要提示 | 2 | 公司基本情況簡介 Company Information | | 本公司董事會、監事會及董事、監事、 高級管理人員保證本報告所 ...

Financial Performance - The total revenue for 2022 was RMB 7,502,987,102.09, representing a 14.37% increase from RMB 6,560,077,586.40 in 2021[4]. - The net profit attributable to shareholders of the listed company was RMB 411,193,683.53, an increase of 17.97% compared to RMB 348,548,495.99 in the previous year[4]. - The operating cash flow net amount reached RMB 758,240,601.50, showing a significant increase of 192.62% from RMB 259,116,960.17 in 2021[4]. - The basic earnings per share increased to RMB 0.62, a rise of 10.71% from RMB 0.56 in the previous year[4]. - The diluted earnings per share also increased to RMB 0.61, reflecting an 8.93% growth compared to RMB 0.56 in 2021[4]. - The total comprehensive income for the year was RMB 413,373,076.38, up from RMB 313,908,790.25 in 2021, showing a growth of 31.69%[49]. - The operating profit for the year ended December 31, 2022, was RMB 476,706,533.91, compared to RMB 425,590,536.88 in 2021, indicating an increase of about 12.0%[54]. Assets and Liabilities - Total assets as of December 31, 2022, were RMB 8,265,131,332.13, up 12.73% from RMB 7,332,033,657.98 at the end of 2021[5]. - The total liabilities increased by 6.37% to RMB 3,915,226,169.32 from RMB 3,680,888,823.85 in the previous year[5]. - The net assets attributable to shareholders of the listed company rose by 18.99% to RMB 4,126,460,390.95 from RMB 3,467,941,567.45 in 2021[5]. - Current liabilities totaled RMB 3,158,485,539.10 as of December 31, 2022, compared to RMB 2,501,880,371.20 in 2021, indicating a significant increase of 26.29%[47]. - Long-term borrowings increased to RMB 545,655,801.48 in 2022 from RMB 346,196,870.64 in 2021, representing a growth of 57.67%[47]. Shareholder Information - As of December 31, 2022, the total number of shareholders was 107,300, including 38 H-share shareholders and 107,262 A-share shareholders[8]. - The proposed final dividend for the year 2022 is RMB 0.20 per share (before tax), subject to shareholder approval[12]. - The largest shareholder, China Hualu Holdings Group Co., Ltd., holds 30.59% of the shares, totaling 204,864,092 shares[10]. - The company emphasizes the importance of shareholder approval for the proposed dividend distribution[12]. - The proposed dividend for 2022 represents a 33.33% increase compared to the previous year's dividend[81]. Cash Flow and Investments - Cash and cash equivalents increased by 55.61% to RMB 1,158,741,565.90 compared to RMB 744,662,302.34 last year, primarily due to net proceeds from a non-public offering of A-shares amounting to RMB 244 million and an increase in customer prepayments[18][20]. - Net cash flow from operating activities reached RMB 758,240,601.50, a substantial increase of 192.62% compared to RMB 259,116,960.17 last year[23][24]. - The company achieved a fixed asset investment of RMB 720 million for the year, representing a year-on-year increase of 21%[30]. Research and Development - Research and development expenses increased by 1.26% to RMB 345,658,511.77 from RMB 341,367,394.20, reflecting ongoing investment in innovation[21]. - The company obtained 7 new product approvals for formulations and 4 for raw materials in 2022, including significant breakthroughs in drug innovation[29]. - The company plans to accelerate the development of new products, focusing on fish oil, hormones, and other specialty raw materials[33]. Market Performance - The sales revenue of the top 10 strategic formulations increased by 30% year-on-year, with the sales of fish oil soft capsules exceeding RMB 10 million[29]. - The international formulations and contract manufacturing sales saw an impressive year-on-year growth of 88%[29]. - The revenue from external transactions for the chemical raw materials segment was RMB 3,171,564,382.95 for the year ended December 31, 2022, compared to RMB 2,740,737,136.77 in 2021, marking an increase of approximately 15.7%[53]. Operational Efficiency - The company achieved a receivables turnover rate of 1,056.89% and an inventory turnover rate of 488.11% as of December 31, 2022[26]. - The company aims to enhance production efficiency and cost control through lean production and procurement management strategies[37]. - The company completed 30 technical quality projects and 21 energy transformation projects, saving RMB 20.9 million in raw material and energy consumption[30]. Compliance and Governance - The audit for the financial statements was conducted by Shinewing Certified Public Accountants, ensuring compliance with Chinese accounting standards[39]. - The company has established an audit committee to oversee financial reporting and internal controls, meeting four times during the year[44].

2021 年 報 Annual Report 2021 Annual Report 年報 山東新華製藥股份有限公司 地址：中國山東省淄博市高新技術產業開發區化工區 郵編：255005 電話：86-533-216 6666 傳真：86-533-228 7508 網址：http://www.xhzy.com Shandong Xinhua Pharmaceutical Company Limited Address: Chemical Industry Area of Zibo Hi-tech Industry Development Zone, Zibo City, Shandong Province, PRC Postal Code: 255005 Tel: 86-533-216 6666 Fax: 86-533-228 7508 Website: http://www.xhzy.com 目錄 CONTENTS 重要提示 本公司董事會、監事會及董事、監 事、高級管理人員保證本報告所載 資料不存在任何虛假記載、誤導性 陳述或者重大遺漏，並對其內容的 真實性、準確性和完整性承擔個別 及連帶責任。 董事長張代銘先生 ...